The resurgence of platinum-based cancer chemotherapy (Q34649255)

3 August 2017

1 reference

title

The resurgence of platinum-based cancer chemotherapy (English)

1 reference

3 August 2017

1 reference

1 reference

Lloyd Kelland

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

12 July 2007

1 reference

3 August 2017

published in

Nature Reviews Cancer

1 reference

3 August 2017

volume

7

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

573-584

1 reference

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

3 August 2017

cites work

1 reference

Platinum Compounds: a New Class of Potent Antitumour Agents

31 March 2020

1 reference

Cisplatin: mode of cytotoxic action and molecular basis of resistance

31 March 2020

1 reference

Protein interactions with platinum-DNA adducts: from structure to function

31 March 2020

1 reference

Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model

31 March 2020

1 reference

Preclinical studies identifying carboplatin as a viable cisplatin alternative

31 March 2020

1 reference

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

31 March 2020

1 reference

Cellular accumulation of the anticancer agent cisplatin: a review

31 March 2020

1 reference

Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

31 March 2020

1 reference

Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin

31 March 2020

1 reference

The internalization and degradation of human copper transporter 1 following cisplatin exposure

31 March 2020

1 reference

Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells

31 March 2020

1 reference

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

31 March 2020

1 reference

The ATP-dependent glutathione S-conjugate export pump

31 March 2020

1 reference

Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.

31 March 2020

1 reference

Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review

31 March 2020

1 reference

Overexpression of metallothionein confers resistance to anticancer drugs.

31 March 2020

1 reference

Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines

31 March 2020

1 reference

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

31 March 2020

1 reference

Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.

31 March 2020

1 reference

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

31 March 2020

1 reference

ERCC1 and clinical resistance to platinum-based therapy

31 March 2020

1 reference

MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.

31 March 2020

1 reference

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

31 March 2020

1 reference

Mismatch repair and treatment resistance in ovarian cancer

31 March 2020

1 reference

Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta.

31 March 2020

1 reference

A role for polymerase eta in the cellular tolerance to cisplatin-induced damage

31 March 2020

1 reference

Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form

31 March 2020

1 reference

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

31 March 2020

1 reference

2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex

31 March 2020

1 reference

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

31 March 2020

1 reference

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

31 March 2020

1 reference

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

31 March 2020

1 reference

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

31 March 2020

1 reference

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

31 March 2020

1 reference

An update on satraplatin: the first orally available platinum anticancer drug

31 March 2020

1 reference

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters

31 March 2020

1 reference

2.4-A crystal structure of the asymmetric platinum complex [Pt(ammine)(cyclohexylamine)]2 bound to a dodecamer DNA duplex

31 March 2020

1 reference

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

31 March 2020

1 reference

Satraplatin: an orally available platinum analog for the treatment of cancer

31 March 2020

1 reference

Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation

31 March 2020

1 reference

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

31 March 2020

1 reference

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

31 March 2020

1 reference

Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin

31 March 2020

1 reference

Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

31 March 2020

1 reference

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

31 March 2020

1 reference

ZD0473 treatment in lung cancer: an overview of the clinical trial results

31 March 2020

1 reference

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473).

31 March 2020

1 reference

DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent

31 March 2020

1 reference

Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group

31 March 2020

1 reference

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

31 March 2020

1 reference

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

31 March 2020

1 reference

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

31 March 2020

1 reference

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer

31 March 2020

1 reference

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors

31 March 2020

1 reference

Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system

31 March 2020

1 reference

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

31 March 2020

1 reference

Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

New approaches to molecular cancer therapeutics

31 March 2020

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

31 March 2020

1 reference

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

31 March 2020

1 reference

Targeting the DNA repair defect of BRCA tumours

31 March 2020

1 reference

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

31 March 2020

1 reference

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors.

31 March 2020

1 reference

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

31 March 2020

1 reference

Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin

31 March 2020

1 reference

Rates of platination of -AG- and -GA- containing double-stranded oligonucleotides: effect of chloride concentration

31 March 2020

1 reference

Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation

31 March 2020

1 reference

Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin

31 March 2020

1 reference

Solution structure of a cisplatin-induced DNA interstrand cross-link

31 March 2020

1 reference

Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1,3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin

31 March 2020

1 reference

Curing metastatic testicular cancer

31 March 2020

1 reference

DNA repair capacity and cisplatin sensitivity of human testis tumour cells

31 March 2020

1 reference

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours

31 March 2020

1 reference

Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2167

1 reference

Dimensions Publication ID

3 August 2017

1030663176

0 references

1 reference